Navigation Links
DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD
Date:6/9/2009

PRINCETON, N.J., June 9 /PRNewswire-FirstCall/ -- DOR BioPharma, Inc. (DOR or the Company) (OTC Bulletin Board: DORB), a late-stage biopharmaceutical company, announced today that it has received Protocol Assistance feedback from the European Medicines Agency (EMEA) on the design of its confirmatory, pivotal, Phase 3 clinical trial evaluating its lead product orBec(R) for the treatment of acute gastrointestinal Graft-versus-Host Disease (GI GVHD).

The EMEA agreed that should the new confirmatory Phase 3 study produce positive results, the data would be sufficient to support a marketing authorization approval in all 27 European Union (EU) member states. In so doing, the EMEA agreed to the primary endpoint and the other principal design features of the new study. The EMEA's response is consistent with feedback previously received from United States Food and Drug Administration (FDA), paving the way for potential approval in the US and EU.

DOR and the FDA reached agreement on the design of the upcoming Phase 3 study via the Special Protocol Assessment (SPA) procedure. An agreement via the SPA procedure is an agreement with the FDA that a Phase 3 clinical trial's design (e.g., endpoints, sample size, control group and statistical analyses) is acceptable to support a regulatory submission seeking new drug approval.

Based on data from the prior Phase 3 study of orBec(R), the upcoming confirmatory Phase 3 clinical trial will be a highly powered, double-blind, randomized, placebo-controlled, multicenter trial and will seek to enroll an estimated 166 patients. The primary endpoint is the treatment failure rate at Study Day 80. This endpoint was successfully measured as a secondary endpoint (p-value = 0.005) in the previous Phase 3 study as a key measure of durability following a 50-day course of treatment with orBec(R) (i.e., 30 days following cessation of treatment). The confirmatory Phase 3 clinical trial wi
'/>"/>

SOURCE DOR BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
2. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
3. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
4. Plasma Products Safe Despite Swine Influenza Outbreak, Assures International Biopharmaceutical Company Octapharma
5. DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation
6. XTL Biopharmaceuticals Announces the Acquisition of the Use Patent on Recombinant Erythropoietin (rHuEPO) for the Treatment of Multiple Myeloma
7. R&D Spending by U.S. Biopharmaceutical Companies Reaches Record Levels in 2008 Despite Economic Challenges
8. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
9. Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.
10. Inspiration Biopharmaceuticals, Inc. Initiates Phase 1 Clinical Trial of IB1001 for the Treatment of Hemophilia B
11. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... it comes to welcoming our new robot overlords, InformationWeek editor ... red carpet. Healthcare is one of the major ... our human sphere. With healthcare concerns top of mind in ... new technologies to help with old problems. That,s where robots ... to increase from $1.7 billion now to $3.7 billion by ...
(Date:7/23/2014)... MEETING, Pa. , July 23, 2014 ... INO) today announced successful results from its ... VGX-3100 in women with biopsy-proven cervical intraepithelial ... (HPV) types 16 or 18. Treatment with ... regression of CIN2/3 to CIN1 or no ...
(Date:7/23/2014)... LOS ANGELES , July 23, 2014  Researchers ... supplementing with calcium elevates calcium levels too ... stones, among other health problems. Women close ... calcium and vitamin D to prevent diseases such as ... "I would recommend that women determine how much calcium ...
Breaking Medicine Technology:Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 2Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 3Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 4Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 5Women Taking Too Much Calcium Create Health Risk 2
... Nov. 8, 2010 GenVec, Inc. (Nasdaq: GNVC ) ... 30, 2010.   GenVec reported a net loss of ... 30, 2010 compared to a net loss of $3.6 million ($0.04 ... months ended September 30, 2010, GenVec,s net loss was $11.3 million ...
... 8, 2010 XStor Medical Systems, Inc. announces the ... quality management system certification is a key step in ... globally. "XStor,s software products are designed under ... codifies our ability to deliver safe & effective solutions. ...
Cached Medicine Technology:GenVec Reports Third Quarter 2010 Financial Results 2GenVec Reports Third Quarter 2010 Financial Results 3GenVec Reports Third Quarter 2010 Financial Results 4GenVec Reports Third Quarter 2010 Financial Results 5
(Date:7/23/2014)... Recently, iFitDress.com, a professional company of women’s dresses ... vintage party dresses . Aside from that, it has ... is up to 63% off. , “We are excited to ... items are all manufactured by trustworthy and experienced workers in ... 30; it is great to provide such a great opportunity ...
(Date:7/23/2014)... (PRWEB) July 23, 2014 A new ... a power morcellator ( http://www.injurybeacon.com/power-morcellator/ ) during minimally ... cancers throughout a woman’s body, Bernstein Liebhard LLP reports. ... the Journal of the American Medical Association, looked at ... morcellator at 500 U.S. hospitals from 2006 to 2012. ...
(Date:7/23/2014)... Steven Reinberg HealthDay Reporter ... obese and overweight American children and teens look in ... U.S. health officials reported Wednesday. "Being overweight or ... high blood pressure, high cholesterol and diabetes," said lead ... Centers for Disease Control and Prevention,s National Center for ...
(Date:7/23/2014)... (PRWEB) July 23, 2014 Home ... in-home care for seniors, is proud to announce the ... featuring experts in a wide range of health and ... social worker and award-winning author Nancy Kriseman, and will ... ways to prevent burnout by becoming more self-aware. In ...
(Date:7/23/2014)... body of research suggesting a safe and effective ... breast cancer, with fewer detrimental side effects and ... The study will be published in final format ... and Endocrinology . , Breast cancer is the ... United States. Approximately 70% of breast cancers are ...
Breaking Medicine News(10 mins):Health News:Cheap 2014 Vintage Party Dresses From Professional Supplier iFitDress.com 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 4Health News:Many Obese U.S. Kids Think They're Thinner Than They Are 2Health News:Many Obese U.S. Kids Think They're Thinner Than They Are 3Health News:Home Care Assistance Calgary to Host Public Webinar on the Topic of Caregiver Mindfulness 2Health News:Home Care Assistance Calgary to Host Public Webinar on the Topic of Caregiver Mindfulness 3Health News:Hormones after breast cancer: Not fuel for the fire after all? 2Health News:Hormones after breast cancer: Not fuel for the fire after all? 3Health News:Hormones after breast cancer: Not fuel for the fire after all? 4Health News:Hormones after breast cancer: Not fuel for the fire after all? 5
... News) -- Older women who take nonsteroidal anti-inflammatory drugs -- ... lower risk of death from colorectal cancer than women who ... Women who reported using these drugs, called NSAIDs, at the ... roughly 30 percent lower rate of death from colorectal cancer ...
... OCTOBER 24, 2011) Heavy alcohol consumption may be ... while higher BMI and increased consumption of black tea ... deadly disease. In three separate studies presented at CHEST ... of Chest Physicians (ACCP), heavy alcohol consumption was related ...
... safe and effective therapy, according to a new long-term ... co-hosted by the Heart and Stroke Foundation and the ... Ottawa Heart Institute heart transplant program revealed results from ... transplant patients. Mean age at transplant was 49 13 ...
... Postmenopausal women who reported having used nonsteroidal anti-inflammatory drugs ... enrollment in the Women,s Health Initiative study had a ... women who reported no use of these drugs at ... International Conference on Frontiers in Cancer Prevention Research, held ...
... October 23, 2011 -- A new study conducted in an ... called "lazy eye," can be achieved in many older children, ... games along with standard amblyopia treatment. Today at the 115th ... Ghosh will report on the approaches that allowed about a ...
... rehabilitation boosts longevity, especially in patients with the lowest ... Cardiovascular Congress 2011, co-hosted by the Heart and Stroke ... benefits to cardiac rehabilitation, regardless of how fit ... cardiac surgery resident and PhD candidate at the University ...
Cached Medicine News:Health News:Can NSAIDs Cut Colorectal Cancer Deaths in Older Women? 2Health News:Heavy alcohol consumption linked to lung cancer 2Health News:Heart transplant surgery safe and effective: A Canadian retrospective spanning 3 decades 2Health News:Heart transplant surgery safe and effective: A Canadian retrospective spanning 3 decades 3Health News:NSAID use associated with lower colorectal cancer mortality rates among postmenopausal women 2Health News:Video games used in new treatment that may fix 'lazy eye' in older children 2Health News:Rehab helps heart patients live longer -- but they have to show up 2Health News:Rehab helps heart patients live longer -- but they have to show up 3
... Ultrapure MB Grade PRODUCT SPECIFICATIONS Form: Granular, free-flowing ... Gel Point (1.5%): 36.0 1.5C Remelt Point ... than or equal to 1,200 gm/cm 2 ... 2,500 gm/cm 2 Moisture: less than or ...
... traces: chloride (Cl) ≤ 3000 mg/kg sulfate (SO 4 ... mg/kg Cd ≤ 10 mg/kg Co ≤ 10 mg/kg ... ≤ 10 mg/kg K ≤ 500 mg/kg Mg ≤ ... mg/kg Ni ≤ 10 mg/kg Pb ≤ 10 mg/kg ...
... a multipurpose agarose, has been developed for ... and separation of high molecular weight DNA ... a high gel strength agarose ( 1800 ... the use of low concentrations of agarose ...
Inquire...
Medicine Products: